Sign in Subscribe
Antineoplastic agents

Serum Uric Acid Levels Linked to Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma

Strategic Insights

— 1 min read

A new study conducted by researchers at Dokuz Eylul University in Izmir, Turkey, has uncovered a significant association between serum uric acid levels and survival outcomes in patients with metastatic renal cell carcinoma treated with targeted therapies. The research, published in the journal BMC Cancer, analyzed the prognostic importance of baseline serum uric acid in 290 patients with a median age of 61. The study found that a serum uric acid level of 5.8 mg/dL was the optimal cut-off point in predicting overall survival in the receiver operating characteristic curve.

Key Takeaways:

  • A total of 290 patients with a median age of 61 were included in the study.
  • The median progression-free survival (PFS) and overall survival (OS) of all patients were 11.6 months and 45 months, respectively.
  • The low-SUA group had superior PFS and OS times than the high-SUA group (16.2 months vs. 8.8 months, p = 0.001).
  • The Kaplan-Meier method was used to estimate PFS and OS in SUA groups.
  • Cox proportional hazard models were performed to evaluate the association between SUA and survival outcomes.
  • The study highlights a noteworthy association between high SUA levels and adverse survival outcomes in patients with RCC treated with targeted therapies.
  • Mehmet Cihan Icli, Hatice Altas, Canberk Sencan, Ahmet Melih Arslan, and others contributed to the research.
  • The study's findings have significant implications for the diagnosis and treatment of metastatic renal cell carcinoma.

Statistics:

  • 290 patients were included in the study.
  • The median age of patients was 61 years.
  • The median PFS and OS of all patients were 11.6 months and 45 months, respectively.
  • The low-SUA group had superior PFS and OS times than the high-SUA group (16.2 months vs. 8.8 months, p = 0.001).
  • The receiver operating characteristic curve determined a serum uric acid level of 5.8 mg/dL as the optimal cut-off point in predicting OS.

Sources:

  • The association between serum uric acid and survival outcomes in patients with metastatic renal cell carcinoma treated with targeted therapy. BMC Cancer, 2025;25(1):1559.
  • Bmc, Campus, 4 Crinan St, London N1 9XW, England (Publisher of BMC Cancer).
  • Dokuz Eylul University, Dept. of Medical Oncology, Izmir, Turkey (Researchers).

Read more